Literature DB >> 22451545

Intraindividual comparison of gadobutrol and gadopentetate dimeglumine for detection of myocardial late enhancement in cardiac MRI.

Francesco De Cobelli1, Antonio Esposito, Gianluca Perseghin, Claudio Sallemi, Elena Belloni, Silvia Ravelli, Chiara Lanzani, Alessandro Del Maschio.   

Abstract

OBJECTIVE: Gadobutrol is an extracellular macrocyclic gadolinium chelate recently introduced in MRI, and it has already been used for cardiac late enhancement imaging; however, until now it has never been compared with gadopentetate dimeglumine. The purpose of our study was to compare 0.1 mmol/kg gadobutrol to 0.2 mmol/kg gadopentetate dimeglumine for the detection of myocardial late enhancement in the same group of patients. SUBJECTS AND METHODS: This was an exploratory single-blind parallel group study comparing gadobutrol (0.1 mmol/kg) to gadopentetate dimeglumine (0.2 mmol/kg) in 20 adult patients scheduled for cardiac late enhancement MRI with gadopentetate dimeglumine and whose MR images showed late enhancement. MR images were acquired at 10, 15, and 20 minutes after peripheral injection of gadobutrol by using a 3D turbo field echo inversion recovery T1-weighted sequence. Volume and percentage of late enhancement, number of involved segments, late enhancement localization and pattern, and late enhancement signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) were compared between contrast agents.
RESULTS: Late enhancement was not significantly different with gadobutrol and gadopentetate dimeglumine both in terms of total volume of myocardium (mean ± SD, 37.8 ± 56.1 and 35.1 ± 46.7 cm(3), respectively; p = 0.33) and percentage of myocardial wall involvement (22.5% ± 19.1% and 22.0% ± 17.2%, respectively; p = 0.67). The number of segments involved was not different (138 with gadobutrol vs 134 with gadopentetate dimeglumine). Furthermore, SNR and CNR were not different (gadopentetate dimeglumine, 123.8 ± 82.9 and gadobutrol, 117.2 ± 88.6, p = 0.58 and gadopentetate dimeglumine, 96.2 ± 68.9 and gadobutrol, 88.4 ± 72.9, p = 0.53, respectively).
CONCLUSION: A single dose of gadobutrol seems to be as effective as a double dose of gadopentetate dimeglumine for the detection of late enhancement.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22451545     DOI: 10.2214/AJR.11.7118

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  7 in total

1.  [Cardiac magnetic resonance imaging: from imaging to diagnosis].

Authors:  M Gutberlet
Journal:  Radiologe       Date:  2013-11       Impact factor: 0.635

2.  Quantitative analysis of late gadolinium enhancement in hypertrophic cardiomyopathy: comparison of diagnostic performance in myocardial fibrosis between gadobutrol and gadopentetate dimeglumine.

Authors:  Dongting Liu; Xiaohai Ma; Jiayi Liu; Lei Zhao; Hui Chen; Lei Xu; Zhonghua Sun; Zhanming Fan
Journal:  Int J Cardiovasc Imaging       Date:  2017-03-13       Impact factor: 2.357

3.  Tissue characterisation and myocardial mechanics using cardiac MRI in children with hypertrophic cardiomyopathy.

Authors:  Sudeep Sunthankar; David A Parra; Kristen George-Durrett; Kimberly Crum; Joshua D Chew; Jason Christensen; Frank J Raucci; Meng Xu; James C Slaughter; Jonathan H Soslow
Journal:  Cardiol Young       Date:  2019-11-26       Impact factor: 1.093

4.  Prospective, randomized comparison of gadopentetate and gadobutrol to assess chronic myocardial infarction applying cardiovascular magnetic resonance.

Authors:  Andre Rudolph; Daniel Messroghli; Florian von Knobelsdorff-Brenkenhoff; Julius Traber; Johannes Schüler; Ralf Wassmuth; Jeanette Schulz-Menger
Journal:  BMC Med Imaging       Date:  2015-11-17       Impact factor: 1.930

5.  High-throughput gadobutrol-enhanced CMR: a time and dose optimization study.

Authors:  Tommaso D'Angelo; Chrysanthos Grigoratos; Silvio Mazziotti; Konstantinos Bratis; Faraz Pathan; Alfredo Blandino; Elen Elen; Valentina O Puntmann; Eike Nagel
Journal:  J Cardiovasc Magn Reson       Date:  2017-11-06       Impact factor: 5.364

6.  Single-Dose Gadoterate Meglumine for 3T Late Gadolinium Enhancement MRI for the Assessment of Chronic Myocardial Infarction: Intra-Individual Comparison with Conventional Double-Dose 1.5T MRI.

Authors:  Jiyeon Lim; Eun-Ah Park; Yong Sub Song; Whal Lee
Journal:  Korean J Radiol       Date:  2018-04-06       Impact factor: 3.500

7.  Image quality of late gadolinium enhancement in cardiac magnetic resonance with different doses of contrast material in patients with chronic myocardial infarction.

Authors:  Caterina Beatrice Monti; Marina Codari; Andrea Cozzi; Marco Alì; Lorenzo Saggiante; Francesco Sardanelli; Francesco Secchi
Journal:  Eur Radiol Exp       Date:  2020-04-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.